Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with  advaced non-small-cell lung cancer (NSCLC) from Czech Republic

Autoři	SKŘIČKOVÁ Jana PEŠEK Miloš ZATLOUKAL Pavel KOLEK Vítězslav SALAJKA František KOUBKOVÁ Leona ZEMANOVÁ Milana SIXTOVÁ Dimka ROUBEC Jaromír COUPKOVÁ Helena TOMÍŠKOVÁ Marcela HRNČIARIK Michal GRYGARKOVÁ Yvona STICHA Michal
Rok publikování	2011
Druh	Konferenční abstrakty
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Popis	The human epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) erlotinib (Tarceva) is approved for use in advanced, pretreated NSCLC. This analysis presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.